Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8ANCF)

Drug Name
Muromonab Drug Info
Indication
Disease Entry ICD 11 Status REF
Organ transplant rejection NE84 Approved [1]
Therapeutic Class
Immunomodulatory Agents
Cross-matching ID
TTD Drug ID
DM8ANCF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting T-cell surface glycoprotein CD3 epsilon (CD3E)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ertumaxomab DM5Z3VP Breast cancer 2C60-2C65 Phase 2 [3]
Resimmune DMT5QSD Cutaneous T-cell lymphoma 2B01 Phase 2 [4]
MT-110 DMPCUN5 Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
Autologous T-cell therapy DMOAET3 Prostate cancer 2C82.0 Phase 1 [6]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell surface glycoprotein CD3 epsilon (CD3E) TTZAT79 CD3E_HUMAN Binder [2]

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 Basiliximab: a review of its use as induction therapy in renal transplantation. Drugs. 2003;63(24):2803-35.
3 Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
4 Resimmune, an anti-CD3 recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma.Haematologica.2015 Jun;100(6):794-800.
5 EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
6 Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.